Earnings report 📈 Stocks 🌍 United States

Xtant Medical Swings to $3.6M Loss, Withdraws 2026 Guidance Amid Strategic Review

Xtant Medical shares face pressure as the company reports a $3.6 million Q3 loss, misses guidance for the second straight quarter, and launches a broad strategic review of its capital structure and operations.

🕐 1 min read

1 assets impacted. Net bias: 0 Bullish, 1 Bearish, 0 Neutral. Strongest signal: XTNT ↓ 7/10 (70% confidence).

📊 Affected Assets (1)

XTNT
Bearish 🤖 70%
📅 Short-term 🌍 US · Explicit

Xtant missed its guidance for the second consecutive quarter, withdrew full-year 2026 guidance without a replacement, and swung to a Q3 2026 net loss of $3.6 million ($0.03/share) from $1.3 million net income a year earlier, with gross margin down to 56.3% from 66.1%. Cash fell to $7.8 million with only $2.1 million of revolver availability. The biologics growth (revenue $19.3 million, +13% y/y) and the board-led strategic review are offsets that could support the stock, but no outcome or timetable is assured.

Catalysts
  • ▼ Board-led strategic review evaluating partnerships, restructurings, financings, acquisitions or dispositions
  • ▼ Biologics revenue of $19.3 million, up 13% year-over-year and 11% quarter-over-quarter, including $2.2 million from HEMOBLAST Bellows
Risk Factors
  • ▲ Second consecutive quarter missing guidance and full-year 2026 guidance withdrawn with no replacement
  • ▲ Net loss of $3.6 million versus prior-year net income of $1.3 million; adjusted EBITDA loss of $1.5 million

🎯 Key Takeaways

  • Q3 2026 net loss reached $3.6 million, or $0.03 per share, compared to a $1.3 million net income in Q3 2025.
  • Total revenue fell to $24.3 million from $33.3 million in the prior-year period.
  • Gross margin contracted to 56.3% from 66.1% in Q3 2025.
  • Cash and cash equivalents declined to $7.8 million as of September 30, 2026, down from $17.1 million at year-end 2025.
  • Biologics revenue grew 13% year-over-year to $19.3 million, including $2.2 million from HEMOBLAST Bellows.

📝 Executive Summary

Xtant Medical Holdings reported a Q3 2026 net loss of $3.6 million, a sharp decline from the $1.3 million profit recorded in the same period last year. Following two consecutive quarters of missed guidance, the company has withdrawn its full-year 2026 outlook and initiated a board-led strategic review to evaluate potential partnerships, restructurings, or asset dispositions to maximize shareholder value.

❓ FAQ

Why did Xtant miss its guidance this quarter?

Total revenue fell to $24.3 million from $33.3 million a year earlier, mainly because of the absence of $5.4 million of divested Coflex/CoFix and international hardware revenue and $5.5 million of wound care licensing revenue, partially offset by $2.2 million of HEMOBLAST revenue. The Chairman called the second consecutive miss 'unacceptable'.

What is the strategic review and could it help the stock?

The Board is reviewing a broad range of alternatives including operational improvements, capital structure changes, partnerships, restructurings, financings, acquisitions and dispositions to maximize stockholder value. No timetable has been set and there is no assurance any action will result.